Dr. Reddy’s Laboratories reported a 9.8% YoY increase in revenue to ₹88.051 billion for Q2 FY26. Global Generics segment led growth, while North America faced price erosion. The company continues to focus on key pipeline assets and business development. Earnings per share reached ₹17.25. Management highlighted growth drivers in branded markets and Nicotine Replacement Therapy.
Financial Performance
Dr. Reddy’s Laboratories (DRL) announced its financial results for the quarter ended September 30, 2025 (Q2 FY26), showcasing a consolidated revenue of ₹88.051 billion, a 9.8% increase compared to the same quarter last year. Earnings per share reached ₹17.25.
Segmental Performance
Global Generics drove revenue, with North America affected by price erosion. The Pharmaceutical Services and Active Ingredients (PSAI) segment also contributed. Key figures include:
- Global Generics Revenue: ₹78.498 billion
- Pharmaceutical Services and Active Ingredients: ₹9.450 billion
Key Business Highlights
- Acquired the STUGERON® portfolio for $50.5 million.
- Launched Linaclotide in India under the brand ‘Colozo®’.
- Partnered with Unitaid, CHAI, and Wits RHI to improve HIV prevention.
Additional Information
- R&D expenses totaled ₹6.202 billion, representing 7.0% of revenues.
- The company continues to address legal and regulatory matters, including ongoing engagement with the SEC and DOJ.
Source: BSE